Research Overview
GLP-2 (Tirzepatide) is a dual incretin receptor agonist studied in research models involving glucose homeostasis, GIP and GLP-1 receptor signaling, energy balance, metabolic regulation, and body composition.
By simultaneously activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, Tirzepatide has become an important research peptide for investigating the coordinated physiological mechanisms that regulate nutrient utilization, endocrine signaling, and metabolic adaptation. Its dual-receptor activity distinguishes it from single-pathway incretin agonists and has generated significant interest across metabolic research.
Lyophilized Vial Format
Precision-manufactured and lyophilized for stability, this research-grade peptide is produced to support reproducible laboratory workflows requiring accurate preparation, controlled storage, and consistent experimental performance.
Why Researchers Study GLP-2 (Tirzepatide)
Tirzepatide is investigated for its ability to engage both GIP and GLP-1 receptor pathways, two complementary signaling systems that play central roles in glucose regulation, energy homeostasis, gastrointestinal physiology, and neuroendocrine communication. Researchers continue to examine how simultaneous activation of these receptors influences metabolic signaling, hormone interactions, and the biological processes involved in energy balance.
Its dual incretin mechanism has established Tirzepatide as a valuable research tool for exploring metabolic physiology, peptide hormone biology, receptor signaling, and the complex molecular networks that govern nutrient sensing and body composition.
Research Applications
Researchers commonly utilize GLP-2 (Tirzepatide) in laboratory investigations involving:
- GIP receptor signaling
- GLP-1 receptor signaling
- Dual incretin biology
- Glucose homeostasis
- Energy homeostasis
- Metabolic regulation
- Endocrine physiology
- Peptide hormone biology
- Body composition research
- Experimental metabolic disease models
